drugset / Trial / NCT07327398
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.
Timeline
- Start
- 2026-01-07
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza virus split vaccine | Vaccine | 0.5 ml | — |
| Subject | Influenza virus split vaccine | Vaccine | 0.7 ml | — |